OCUGEN, INC. Cash and Cash Equivalents, Period Increase (Decrease)
OCUGEN, INC. (OCGN) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$24.83 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-15.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-15
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was -$3.72M.
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was $236.00K, a 98.93% decline year-over-year.
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$5.81M.
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$15.53M.
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$24.83M, a 2600.20% decline from fiscal 2016.
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $993.00K.
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$27.61M, a 155.45% decline from fiscal 2014.
- OCUGEN, INC. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $49.79M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2017-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | -$3.48M derived: sum of 2 quarters · filed 2018-03-15 | -$9.29M derived: sum of 3 quarters · filed 2018-03-15 | -$24.83M 10-K · filed 2018-03-15 |
| 2017-09-30 | $236.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$5.58M derived: sum of 2 quarters · filed 2017-11-09 | -$21.11M 10-Q · filed 2017-11-09 | -$27.20M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-06-30 | -$5.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$21.35M 10-Q · filed 2017-08-10 | -$27.43M derived: sum of 3 quarters · filed 2018-03-15 | -$5.36M derived: sum of 4 quarters · filed 2018-03-15 |
| 2017-03-31 | -$15.53M 10-Q · filed 2017-05-11 | -$21.62M derived: sum of 2 quarters · filed 2018-03-15 | $448.00K derived: sum of 3 quarters · filed 2018-03-15 | -$6.52M derived: sum of 4 quarters · filed 2018-03-15 |
| 2016-12-31 | -$6.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-15 | $15.98M derived: sum of 2 quarters · filed 2018-03-15 | $9.01M derived: sum of 3 quarters · filed 2018-03-15 | $993.00K 10-K · filed 2018-03-15 |
| 2016-09-30 | $22.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $15.10M derived: sum of 2 quarters · filed 2017-11-09 | $7.08M 10-Q · filed 2017-11-09 | -$196.00K derived: sum of 4 quarters · filed 2017-11-09 |
| 2016-06-30 | -$6.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$14.99M 10-Q · filed 2017-08-10 | -$22.26M derived: sum of 3 quarters · filed 2017-08-10 | -$29.76M derived: sum of 4 quarters · filed 2017-08-10 |
| 2016-03-31 | -$8.02M 10-Q · filed 2017-05-11 | -$15.29M derived: sum of 2 quarters · filed 2017-05-11 | -$22.79M derived: sum of 3 quarters · filed 2017-05-11 | -$30.75M derived: sum of 4 quarters · filed 2017-05-11 |
| 2015-12-31 | -$7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$14.77M derived: sum of 2 quarters · filed 2017-03-16 | -$22.73M derived: sum of 3 quarters · filed 2017-03-16 | -$27.61M 10-K · filed 2017-03-16 |
| 2015-09-30 | -$7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$15.46M derived: sum of 2 quarters · filed 2016-11-10 | -$20.34M 10-Q · filed 2016-11-10 | $34.93M derived: sum of 4 quarters · filed 2016-11-10 |
| 2015-06-30 | -$7.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$12.84M 10-Q · filed 2016-08-11 | $42.43M derived: sum of 3 quarters · filed 2016-08-11 | $37.91M derived: sum of 4 quarters · filed 2016-08-11 |
| 2015-03-31 | -$4.88M 10-Q · filed 2016-05-12 | $50.39M derived: sum of 2 quarters · filed 2016-05-12 | $45.87M derived: sum of 3 quarters · filed 2016-05-12 | $50.29M derived: sum of 4 quarters · filed 2016-05-12 |
| 2014-12-31 | $55.27M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $50.75M derived: sum of 2 quarters · filed 2016-03-10 | $55.17M derived: sum of 3 quarters · filed 2016-03-10 | $49.79M 10-K · filed 2016-03-10 |
| 2014-09-30 | -$4.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | -$102.00K derived: sum of 2 quarters · filed 2015-11-12 | -$5.48M 10-Q · filed 2015-11-12 | |
| 2014-06-30 | $4.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$958.00K 10-Q · filed 2015-08-12 | ||
| 2014-03-31 | -$5.37M 10-Q · filed 2015-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |